Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect - PubMed (original) (raw)
Clinical Trial
. 2003 Oct;285(4):E701-7.
doi: 10.1152/ajpendo.00024.2003. Epub 2003 May 28.
Affiliations
- PMID: 12773303
- DOI: 10.1152/ajpendo.00024.2003
Free article
Clinical Trial
Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect
Ronald L Prigeon et al. Am J Physiol Endocrinol Metab. 2003 Oct.
Free article
Abstract
Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that stimulates insulin secretion and decreases glucagon release. It has been hypothesized that GLP-1 also reduces glycemia independent of its effect on islet hormones. Based on preliminary evidence that GLP-1 has independent actions on endogenous glucose production, we undertook a series of experiments that were optimized to address this question. The effect of GLP-1 on glucose appearance (Ra) and glucose disposal (Rd) was measured in eight men during a pancreatic clamp that was performed by infusing octreotide to suppress secretion of islet hormones, while insulin and glucagon were infused at rates adjusted to maintain blood glucose near fasting levels. After stabilization of plasma glucose and equilibration of [3H]glucose tracer, GLP-1 was given intravenously for 60 min. Concentrations of insulin, C-peptide, and glucagon were similar before and during the GLP-1 infusion (115 +/- 14 vs. 113 +/- 11 pM; 0.153 +/- 0.029 vs. 0.156 +/- 0.026 nM; and 64.7 +/- 11.5 vs. 65.8 +/- 13.8 ng/l, respectively). With the initiation of GLP-1, plasma glucose decreased in all eight subjects from steady-state levels of 4.8 +/- 0.2 to a nadir of 4.1 +/- 0.2 mM. This decrease in plasma glucose was accounted for by a significant 17% decrease in Ra, from 22.6 +/- 2.8 to 19.1 +/- 2.8 micromol. kg-1. min-1 (P < 0.04), with no significant change in Rd. These findings indicate that, under fasting conditions, GLP-1 decreases endogenous glucose production independent of its actions on islet hormone secretion.
Similar articles
- No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects.
Toft-Nielsen M, Hvidberg A, Hilsted J, Dige-Petersen H, Holst JJ. Toft-Nielsen M, et al. Diabet Med. 1996 Jun;13(6):544-8. doi: 10.1002/(SICI)1096-9136(199606)13:6<544::AID-DIA129>3.0.CO;2-X. Diabet Med. 1996. PMID: 8799658 Clinical Trial. - Incretin and islet hormonal responses to fat and protein ingestion in healthy men.
Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF, Ahrén B. Carr RD, et al. Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E779-84. doi: 10.1152/ajpendo.90233.2008. Epub 2008 Jul 8. Am J Physiol Endocrinol Metab. 2008. PMID: 18612044 - Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ. Nauck MA, et al. Regul Pept. 2004 Nov 15;122(3):209-17. doi: 10.1016/j.regpep.2004.06.020. Regul Pept. 2004. PMID: 15491793 - [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
Otto Buczkowska E, Dworzecki T. Otto Buczkowska E, et al. Przegl Lek. 2004;61(9):947-50. Przegl Lek. 2004. PMID: 15803906 Review. Polish. - Effects of glucagon-like peptide 1 on the hepatic glucose metabolism.
D'Alessio D, Vahl T, Prigeon R. D'Alessio D, et al. Horm Metab Res. 2004 Nov-Dec;36(11-12):837-41. doi: 10.1055/s-2004-826172. Horm Metab Res. 2004. PMID: 15655716 Review.
Cited by
- Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.
Dietsche KB, Magge SN, Dixon SA, Davis FS, Krenek A, Chowdhury A, Mabundo L, Stagliano M, Courville AB, Yang S, Turner S, Cai H, Kasturi K, Sherman AS, Ha J, Shouppe E, Walter M, Walter PJ, Chen KY, Brychta RJ, Peer C, Zeng Y, Figg W, Cogen F, Estrada DE, Chacko S, Chung ST. Dietsche KB, et al. J Clin Endocrinol Metab. 2024 Apr 19;109(5):1361-1370. doi: 10.1210/clinem/dgad669. J Clin Endocrinol Metab. 2024. PMID: 37967247 Free PMC article. Clinical Trial. - Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.
Salehi M, Aulinger B, Prigeon RL, D'Alessio DA. Salehi M, et al. Diabetes. 2010 Jun;59(6):1330-7. doi: 10.2337/db09-1253. Epub 2010 Mar 9. Diabetes. 2010. PMID: 20215429 Free PMC article. - The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
He YL, Sadler BM, Sabo R, Balez S, Wang Y, Campestrini J, Laurent A, Ligueros-Saylan M, Howard D. He YL, et al. Clin Pharmacokinet. 2007;46(9):787-802. doi: 10.2165/00003088-200746090-00006. Clin Pharmacokinet. 2007. PMID: 17713976 Clinical Trial. - Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
Salehi M, Vahl TP, D'Alessio DA. Salehi M, et al. J Clin Endocrinol Metab. 2008 Dec;93(12):4909-16. doi: 10.1210/jc.2008-0605. Epub 2008 Sep 30. J Clin Endocrinol Metab. 2008. PMID: 18827000 Free PMC article. - From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options.
Gastaldelli A, Cusi K. Gastaldelli A, et al. JHEP Rep. 2019 Jul 19;1(4):312-328. doi: 10.1016/j.jhepr.2019.07.002. eCollection 2019 Oct. JHEP Rep. 2019. PMID: 32039382 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous